We have studied the effects of moguisteine, a new non-narcotic, peripherally acting antitussive compound, on tracheobronchial rapidly adapting irritant receptors (RARs). Experiments were carried out on dogs anaesthetized with a mixture of urethane and alpha-chloralose, paralysed with gallamine, vagotomized and artificially ventilated. Single unit action potentials identified as originating from tracheobronchial RARs were recorded from the peripheral cut end of the right vagus nerve. The activity of these receptors was recorded together with oesophageal pressure and arterial blood pressure. Fourteen RARs were challenged with moguisteine (200 microg x kg[-1] i.v.) in 0.4% dimethylsulphoxide (DMSO) or 0.4% DMSO alone (vehicle). Receptor activity was recorded before (control) and at 2, 5, 10, 15, 20, 30 and 45 min after administration of the challenging compounds. When the results at intervals of 2, 5, 10, 15 and 20 min were averaged for each dog, it was found that moguisteine decreased the mean activity of the 14 receptors to 75% of the control value (p<0.05); the greatest inhibition occurred 10-20 min after moguisteine administration. DMSO did not significantly affect the activity of these endings. Oesophageal pressure, arterial blood pressure and cardiac frequency were not altered during the experimental procedures. The overall results indicate the presence of an inhibitory effect of moguisteine on rapidly adapting irritant receptors that could account for the antitussigenic effect of this compound.

Download full-text PDF

Source
http://dx.doi.org/10.1183/09031936.98.11020339DOI Listing

Publication Analysis

Top Keywords

tracheobronchial rapidly
8
rapidly adapting
8
activity receptors
8
action moguisteine
4
activity
4
moguisteine activity
4
activity tracheobronchial
4
receptors
4
adapting receptors
4
receptors dog
4

Similar Publications

Traumatic tracheobronchial tree injuries are rarely survivable. We present the case of a 31-year-old male patient who had a delayed discovery of a complete right mainstem bronchus avulsion following a motor vehicle collision. Despite initial respiratory stability, the patient rapidly deteriorated on hospital day 4.

View Article and Find Full Text PDF
Article Synopsis
  • Relapsing Polychondritis (RP) is a rare and serious inflammatory disease that can lead to life-threatening airway collapse.
  • A patient who was misdiagnosed with refractory asthma experienced severe airway collapse, requiring advanced treatments like bronchoscopic laser tracheobronchoplasty and stent placement.
  • After successful stabilization and discharge, the patient managed their symptoms with a tapering glucocorticoid regimen and did not require rehospitalization.
View Article and Find Full Text PDF

The average cost to bring a new drug from its initial discovery to a patient's bedside is estimated to surpass $2 billion and requires over a decade of research and development. There is a need for new drug screening technologies that can parse drug candidates with increased likelihood of clinical utility early in development in order to increase the cost-effectiveness of this pipeline. For example, during the COVID-19 pandemic, resources were rapidly mobilized to identify effective therapeutic treatments but many lead antiviral compounds failed to demonstrate efficacy when progressed to human trials.

View Article and Find Full Text PDF

Microscopic polyangiitis (MPA) is a rare autoimmune disease characterized by the inflammation and necrosis of small vessels, primarily affecting kidneys and lungs. It is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) due to the presence of ANCA. MPA can manifest as diffuse alveolar hemorrhage (DAH) and rapidly progressive glomerulonephritis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!